Daan Gene Co., Ltd.
002030.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.54B
Close$
$3.11
42.1% downside
Current Fair Value
42.1% downsideOvervalued by 42.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.54 Billion |
|---|---|
| Enterprise Value | $7.13 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.43 |
| Outstanding Shares | 1,403,446,032 |
Return
| Return on Equity | -9.73% |
|---|---|
| Return on Assets | -8.16% |
| Return on Invested Capital | -9.21% |
Valuation & Multiples
| P/E Ratio | -11.03 |
|---|---|
| PEG | 12.18 |
| Price to Sales | - |
| Price to Book Ratio | 1.07 |
| Enterprise Value to Revenue | 9.55 |
| Enterprise Value to EBIT | -10.4 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Daan Gene Co., Ltd.
1,506 employees
CEO: Yang Wang Daan Gene Co., Ltd. specializes in the research, development, manufacturing, and commercialization of clinical diagnostic reagents and instruments. The company's extensive product portfolio encompasses advanced solutions such as fluoresc...